Key result
Omega-3 cardiovascular trials require improved study designs addressing dosing and baseline status to assess outcomes accurately.
Answers are grounded in this paper and cite their sources.
In contrast to earlier long-chain (LC) omega-3 (i.e. EPA and DHA) investigations, some recent studies have not demonstrated significant effects of EPA and DHA on cardiovascular disease (CVD) outcomes. The neutral findings may have been due to experimental design issues, such as: maintenance on aggressive cardiovascular drug treatment overshadowing the benefits of LC omega-3s, high background LC omega-3 intake, too few subjects in the study, treatment duration too short, insufficient LC omega-3 dosage, increase in omega-6 fatty acid intake during the study, failure to assess the LC omega-3 status of the subjects prior to and during treatment and lack of clarity concerning which mechanisms were expected to produce benefits. At the 11th ISSFAL Congress, a workshop was held on conducting LC omega-3 clinical trials with cardiovascular outcomes, with the goal of gaining a better understanding concerning aspects of experimental design that should be considered when planning clinical studies related to EPA and DHA and potential cardiovascular benefits.
No takes yet. Share an insight, caveat, or question.
Rice et al. (2016) conducted a review in Cardiovascular disease. Long-chain omega-3 fatty acids (EPA and DHA) was evaluated on Cardiovascular disease outcomes. Long-chain omega-3 (EPA and DHA) clinical trials require improved experimental design—addressing dosing, background intake, and baseline status—to accurately assess cardiovascular outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: